Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...

Investors are worried how the company will handle the 2028 expiration of the U.S. patents protecting Keytruda, Merck’s ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep” or 'the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for ...

Thomas Edward Fuller III, of the 2000 block of Kriebel Road in Towamencin and also of Dana Avenue in Bensalem, was charged ...